| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
IACS-8968 targets indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), the two key enzymes that catalyze the rate-limiting first step of tryptophan catabolism along the kynurenine pathway. By inhibiting these enzymes, IACS-8968 reduces the production of immunosuppressive kynurenines, thereby modulating the tumor microenvironment and potentially enhancing anti-tumor immune responses. The compound exhibits a pIC₅0 of 6.43 for IDO and less than 5 for TDO.
|
|---|---|
| ln Vitro |
In vitro, IACS-8968 demonstrates potent inhibition of IDO and TDO enzymes. It has a pIC₅0 of 6.43 for IDO, indicating high potency at low nanomolar concentrations. Its inhibitory activity on TDO is less potent, with a pIC₅0 of less than 5. This dual inhibition profile makes it a valuable tool for studying the role of the kynurenine pathway in immune suppression and tumor progression. The compound is typically assessed using enzyme activity assays with recombinant proteins or cell-based systems.
|
| ln Vivo |
In vivo studies of IACS-8968 are likely focused on evaluating its immunomodulatory and anti-tumor efficacy in animal models. As an IDO/TDO inhibitor, it is expected to reverse IDO-mediated immune suppression and enhance anti-tumor immune responses, potentially in combination with other immunotherapies. The compound is used as a research tool to study immune evasion mechanisms, tumor immunology, and inflammatory regulation. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profiles.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, IACS-8968 is evaluated using enzymatic activity assays that measure IDO1 and TDO-mediated conversion of tryptophan to N-formylkynurenine. The compound is incubated with recombinant IDO1 or TDO enzyme, tryptophan, and appropriate cofactors at various concentrations. The reaction product, kynurenine, is quantified by spectrophotometric or HPLC methods. IC₅0 or pIC₅0 values are determined from dose-response curves. Selectivity profiling against other enzymes may be performed to confirm specificity.
|
| Cell Assay |
For in vitro cellular experiments, IACS-8968 is typically tested in cells that express IDO1 or TDO, such as cancer cell lines or immune cells. Cells are cultured in appropriate media and treated with various concentrations of the compound. IDO/TDO activity is measured by quantifying kynurenine levels in the culture supernatant using colorimetric or HPLC-based methods. The compound's effects on T cell proliferation and function can be assessed in co-culture systems with IDO-expressing cells and T cells.
|
| Animal Protocol |
For in vivo animal experiments, IACS-8968 can be administered to tumor-bearing mice via various routes, including oral gavage, intravenous injection, or intraperitoneal injection. Syngeneic mouse tumor models that express IDO1 or TDO are commonly used to evaluate the immunomodulatory and antitumor effects of IDO/TDO inhibition. Typical dosing regimens may range from 1 to 100 mg/kg. Tumor volume, immune cell infiltration, and kynurenine levels in plasma and tumor tissues are measured as pharmacodynamic markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of IACS-8968 are not extensively detailed in the provided references. As a small molecule with a molecular weight of 381.35, it is likely to have reasonable bioavailability and tissue distribution. The compound is soluble in DMSO at 50 mg/mL. Detailed parameters such as Cₘₐₓ, Tₘₐₓ, AUC, half-life, and clearance would need to be determined through comprehensive PK studies. Its metabolism and excretion pathways remain to be fully characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for IACS-8968 are limited, as it is primarily a research tool. As an IDO/TDO inhibitor, its toxicity would depend on the importance of the kynurenine pathway for normal immune function and metabolism. Comprehensive toxicology studies including acute and repeated-dose toxicity, genotoxicity, and cardiotoxicity assessments would be needed for further development. Appropriate safety precautions should be taken when handling this compound.
|
| References | |
| Additional Infomation |
IACS-8968 is a research compound used to study IDO/TDO biology and evaluate IDO/TDO-targeted immunomodulatory strategies. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound's dual IDO and TDO inhibition makes it a valuable tool for investigating the role of the kynurenine pathway in immune evasion and tumor immunology.
|
| Molecular Formula |
C17H18F3N5O2
|
|---|---|
| Molecular Weight |
381.352333545685
|
| Exact Mass |
381.141
|
| CAS # |
2144425-14-7
|
| Related CAS # |
IACS-8968 R-enantiomer;2239305-67-8;IACS-8968 S-enantiomer;2239305-70-3
|
| PubChem CID |
132060309
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
27
|
| Complexity |
655
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2(CCN(C3N4C=NC=C4C=C(C(F)(F)F)C=3)CC2(C)C)C(=O)NC1=O
|
| InChi Key |
UBMTZODMRPHSBC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18F3N5O2/c1-15(2)8-24(4-3-16(15)13(26)22-14(27)23-16)12-6-10(17(18,19)20)5-11-7-21-9-25(11)12/h5-7,9H,3-4,8H2,1-2H3,(H2,22,23,26,27)
|
| Chemical Name |
6,6-dimethyl-8-(7-(trifluoromethyl)imidazo[1,5-a]pyridin-5-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione
|
| Synonyms |
IACS-8968 IACS 8968 IACS8968
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~131.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6223 mL | 13.1113 mL | 26.2226 mL | |
| 5 mM | 0.5245 mL | 2.6223 mL | 5.2445 mL | |
| 10 mM | 0.2622 mL | 1.3111 mL | 2.6223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
